MA29688B1 - Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine - Google Patents

Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine

Info

Publication number
MA29688B1
MA29688B1 MA30568A MA30568A MA29688B1 MA 29688 B1 MA29688 B1 MA 29688B1 MA 30568 A MA30568 A MA 30568A MA 30568 A MA30568 A MA 30568A MA 29688 B1 MA29688 B1 MA 29688B1
Authority
MA
Morocco
Prior art keywords
formulation
plaquetry
thienopyridine
aggregation inhibitor
aggregation
Prior art date
Application number
MA30568A
Other languages
English (en)
Inventor
David Brian Dziennik
Tamara Beth Edelman
Peter Lloyd Oren
Robert Louis Ternik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37198935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29688(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA29688B1 publication Critical patent/MA29688B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention concerne une formulation d'un composé de formule (I), un procédé de préparation correspondant et des méthodes pour utiliser ladite formulation.
MA30568A 2005-06-10 2008-01-09 Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine MA29688B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68918305P 2005-06-10 2005-06-10

Publications (1)

Publication Number Publication Date
MA29688B1 true MA29688B1 (fr) 2008-08-01

Family

ID=37198935

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30568A MA29688B1 (fr) 2005-06-10 2008-01-09 Formulation d'un inhibiteur de l'agregation plaquettaire thienopyridine

Country Status (34)

Country Link
US (1) US20080176893A1 (fr)
EP (1) EP1896019B1 (fr)
JP (1) JP2008543755A (fr)
KR (2) KR20100076050A (fr)
CN (1) CN101193633B (fr)
AR (1) AR054283A1 (fr)
AT (1) ATE441413T1 (fr)
AU (1) AU2006258102B2 (fr)
BR (1) BRPI0611350B8 (fr)
CA (1) CA2611668C (fr)
CY (1) CY1109502T1 (fr)
DE (1) DE602006008942D1 (fr)
DK (1) DK1896019T3 (fr)
DO (1) DOP2006000126A (fr)
EA (1) EA011693B1 (fr)
EC (1) ECSP077984A (fr)
ES (1) ES2330373T3 (fr)
HR (1) HRP20090516T1 (fr)
IL (1) IL187830A0 (fr)
MA (1) MA29688B1 (fr)
MX (1) MX2007015431A (fr)
MY (1) MY151038A (fr)
NO (1) NO20076317L (fr)
NZ (1) NZ564003A (fr)
PE (1) PE20070320A1 (fr)
PL (1) PL1896019T3 (fr)
PT (1) PT1896019E (fr)
RS (1) RS51194B (fr)
SI (1) SI1896019T1 (fr)
TN (1) TNSN07466A1 (fr)
TW (1) TWI318571B (fr)
UA (1) UA91051C2 (fr)
WO (1) WO2006135605A2 (fr)
ZA (1) ZA200710697B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100606A4 (fr) * 2006-12-07 2009-12-30 Daiichi Sankyo Co Ltd Préparation revêtue d'un film ayant une stabilité améliorée
CN101568339A (zh) * 2006-12-07 2009-10-28 伊莱利利公司 普拉格雷的制品
TWI482641B (zh) * 2006-12-07 2015-05-01 Daiichi Sankyo Co Ltd 含有低取代度羥丙基纖維素之醫藥組成物
US20100280064A1 (en) * 2006-12-07 2010-11-04 Tomoyuki Watanabe Pharmaceutical composition having improved storage stability
CA2672157C (fr) * 2006-12-07 2016-07-26 Daiichi Sankyo Company, Limited Procede de production d'une preparation solide
CA2672134C (fr) * 2006-12-07 2015-02-10 Daiichi Sankyo Company, Limited Preparation medicale sous forme solide contenant un mannitol ou un lactose
CN101675058A (zh) * 2007-03-02 2010-03-17 第一三共株式会社 用于制备高纯度普拉格雷盐酸盐的方法
US8343995B2 (en) 2007-04-27 2013-01-01 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
US20110003847A1 (en) 2008-02-06 2011-01-06 Helm Ag Prasugrel Salts with Improved Properties
EP2107061A1 (fr) * 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement
ES2353853T3 (es) * 2008-04-25 2011-03-07 Sandoz Ag SAL HIDROGENOSULFATO DE 2-ACETOXI-5-("ALFA"-CICLOPROPILCARBONIL-2-FLUORBENCIL)-4,5,6,7-TETRAHIDROTIENO[3,2-c]PIRIDINA Y SU PREPARACIÓN.
SI2398468T1 (sl) * 2009-02-17 2017-03-31 Krka, D.D., Novo Mesto Farmacevtske sestave, ki obsegajo prasugrel ali njegove farmacevtsko sprejemljive kislinske adicijske soli in postopek za njihovo pripravo
CN102625658B (zh) 2009-05-13 2015-01-28 锡德克斯药物公司 包含普拉格雷和环糊精衍生物的药物组合物及其制备和使用方法
DE102009036646A1 (de) 2009-08-07 2011-02-10 Ratiopharm Gmbh Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon
WO2011052499A1 (fr) * 2009-10-28 2011-05-05 第一三共株式会社 Composition pharmaceutique présentant une stabilité au stockage améliorée
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
WO2011092720A2 (fr) * 2010-02-01 2011-08-04 Msn Laboratories Limited Composition pharmaceutique de prasugrel et ses sels pharmaceutiquement acceptables
TR201007926A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Prasugrel tablet formülasyonları.
EP2409685A3 (fr) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel à désintégration orale
TR201005900A1 (tr) 2010-07-19 2012-02-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Geliştirilmiş stabiliteye sahip prasugrel granülleri.
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
CZ2011872A3 (cs) 2011-12-22 2013-07-03 Zentiva, K.S. Farmaceutická formulace prasugrelu hydrobromidu
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2014060560A1 (fr) 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations orales solides de prasugrel
EP2722037A1 (fr) 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations de prasugrel
CN102993210A (zh) * 2012-12-19 2013-03-27 苏春华 一种吡啶并噻吩的新化合物
EP2979693A1 (fr) 2014-08-01 2016-02-03 Zaklady Farmaceutyczne Polpharma SA Composition pharmaceutique comprenant du prasugrel ou un sel pharmaceutiquement acceptable de celui-ci et son procédé de préparation
WO2016122421A1 (fr) 2015-01-29 2016-08-04 Pharmactive Ilaç Sanayi Ve Ticaret A.Ş. Compositions pharmaceutiques stables contenant une base de prasugrel
EP3158993A1 (fr) 2015-10-22 2017-04-26 Zaklady Farmaceutyczne Polpharma SA Procédé pour préparer un comprimé contenant du prasugrel ou des sels pharmaceutiquement acceptables de celui-ci
CN107304216A (zh) * 2016-04-20 2017-10-31 陕西合成药业股份有限公司 噻吩吡啶类衍生物及其制备方法和用途
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
GR1009230B (el) 2016-10-12 2018-02-22 Φαρματεν Αβεε Φαρμακευτικο σκευασμα που περιλαμβανει βεσυλικη πρασουγρελη

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
PL208386B1 (pl) * 2000-07-06 2011-04-29 Daiichi Sankyo Company Sole addycyjne 2-acetoksy-5-(α-cyklopropylokarbonylo-2-flurobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, lekarstwo zawierające jako składnik czynny te sole, zastosowanie soli, sposoby wytwarzania soli addycyjnych 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny z kwasem, sposób wytwarzania chlorowodorku 2-acetoksy-5-(α-cyklopropylokarbonylo-2-fluorobenzylo)-4,5,6,7-tetrahydrotieno[3,2-c]pirydyny
EP1243524A3 (fr) * 2001-03-16 2004-04-07 Pfizer Products Inc. Trousse pharmaceutique pour médicaments sensibles a l'oxygène
JP4394873B2 (ja) * 2001-12-19 2010-01-06 武田薬品工業株式会社 酸素に不安定な化合物を含有する固形組成物およびその安定化方法
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
PL1653930T3 (pl) * 2003-08-05 2008-06-30 Zentiva Ks Sposoby stabilizacji atorwastatyny

Also Published As

Publication number Publication date
AU2006258102A1 (en) 2006-12-21
BRPI0611350B8 (pt) 2021-05-25
NZ564003A (en) 2011-07-29
BRPI0611350B1 (pt) 2020-09-15
AR054283A1 (es) 2007-06-13
CA2611668C (fr) 2013-10-15
CY1109502T1 (el) 2014-08-13
UA91051C2 (ru) 2010-06-25
AU2006258102B2 (en) 2011-09-15
MX2007015431A (es) 2008-02-21
NO20076317L (no) 2008-02-29
HK1116422A1 (en) 2008-12-24
BRPI0611350A2 (pt) 2010-12-07
EP1896019B1 (fr) 2009-09-02
CN101193633B (zh) 2011-12-14
SI1896019T1 (sl) 2010-01-29
TNSN07466A1 (en) 2009-03-17
DOP2006000126A (es) 2006-12-15
ES2330373T3 (es) 2009-12-09
EA200702670A1 (ru) 2008-04-28
KR20080008413A (ko) 2008-01-23
CA2611668A1 (fr) 2006-12-21
EA011693B1 (ru) 2009-04-28
WO2006135605A2 (fr) 2006-12-21
ATE441413T1 (de) 2009-09-15
ECSP077984A (es) 2008-01-23
DK1896019T3 (da) 2009-10-26
JP2008543755A (ja) 2008-12-04
TWI318571B (en) 2009-12-21
ZA200710697B (en) 2009-08-26
CN101193633A (zh) 2008-06-04
RS51194B (sr) 2010-10-31
MY151038A (en) 2014-03-31
US20080176893A1 (en) 2008-07-24
PT1896019E (pt) 2009-11-19
PL1896019T3 (pl) 2010-01-29
IL187830A0 (en) 2008-04-13
TW200718420A (en) 2007-05-16
PE20070320A1 (es) 2007-05-12
WO2006135605A3 (fr) 2007-04-12
HRP20090516T1 (hr) 2009-10-31
DE602006008942D1 (en) 2009-10-15
KR20100076050A (ko) 2010-07-05
EP1896019A2 (fr) 2008-03-12

Similar Documents

Publication Publication Date Title
EA200870321A1 (ru) Способ получения 4-оксохинолинового соединения
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
MA40225B1 (fr) Composés dihydroisoquinolinone substitués
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
MA31763B1 (fr) Inhibiteurs de kinase de type polo
EA201000883A1 (ru) Производные индолинона и способ их получения
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
AU2008303600A8 (en) 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives
MX2009005649A (es) Tratamiento para mieloma multiple.
MA31080B1 (fr) Dérivés cyclisés en tant qu'inhibiteurs d'eg-5.
MA30757B1 (fr) Inhibiteurs de l'akt (proteine kinase b)
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
MX2007014172A (es) Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.